论文部分内容阅读
目的：为建立与联合化疗相适应的体外联合药敏试验。方法：用Ｃｈｏｕ＇ｓ半效原则分析法摸索出ＨＡ、ＤＡ、ＡＡ、ＭＡ、ＨＡＤ、ＨＡＡ、ＨＡＭ７种化疗方案各药之间的最佳联合比例，按这种比例关系，用ＭＴＴ法测定了７９例急性非淋巴细胞白血病（ＡＮＬＬ）患者对该７种方案的体外敏感性。结果（体外／体内，Ｓ：敏感，Ｒ：耐药）：Ｓ／Ｓ６７例，Ｒ／Ｒ９例，Ｒ／Ｓ２例，Ｓ／Ｒ１例。与临床总符合率９６．２％；阳性符合率９８．５％；阴性符合率８１．８％；试验敏感性９７．１％；特异性８８．９％。结论：该研究探索的体外联合药敏试验与临床治疗敏感性有很好的相关性，试验敏感性与单药药敏试验相当，特异性优于单药药敏试验。
Objective: To establish an in vitro combined drug susceptibility test that is compatible with combination chemotherapy. Methods: The optimal combination ratio of HA, DA, AA, MA, HAD, HAA, and HAM 7 chemotherapy drugs was explored using the Chou’s semi-effective principle analysis method. According to this ratio, the MTT method was used to determine the optimal combination ratio. In vitro sensitivity of 79 acute lymphoblastic leukemia (ANLL) patients to the 7 regimens. Results (in vitro/in vivo, S: sensitive, R: resistant): S/S 67 cases, R/R 9 cases, R/S 2 cases, S/R 1 cases. The overall compliance rate was 96.2%; the positive coincidence rate was 98.5%; the negative coincidence rate was 81.8%; the test sensitivity was 97.1%; the specificity was 88.9%. Conclusion: The in vitro combined drug susceptibility test in this study has a good correlation with the sensitivity of clinical treatment. The sensitivity of the test is comparable to the single drug susceptibility test, and the specificity is better than the single drug susceptibility test.